FDA Commissioner on revised food coloring rules

Food Dye Regulations, Drug Approvals & US Manufacturing: An FDA Update

Key Concepts:

• Petroleum-based Dyes: Artificial food colorings derived from petroleum, facing increasing scrutiny due to potential health concerns.
• Natural Dyes: Colorings sourced from natural ingredients, now gaining FDA recognition and expanded approval.
• Expedited Voucher Program: FDA initiative to accelerate drug approval processes, aiming for timelines of 1-2 months.
• Idle Time (in FDA processes): Periods of inactivity or delay within the FDA’s review and approval workflows.
• Reshoring/Onshoring: The process of bringing manufacturing back to the United States.
• America First Agenda: A nationalistic policy prioritizing domestic interests, including manufacturing and supply chain security.

I. Changes to Food Dye Labeling Regulations

The FDA is revising labeling regulations concerning food dyes, focusing on increasing the use of non-petroleum-based alternatives. The core issue addressed is the inaccuracy of the “no artificial dyes” label, which previously didn’t account for colorings derived from natural sources. The FDA now recognizes natural ingredients that create color and allows their inclusion under the “no artificial colors” label.

Two additional natural dyes have been approved, providing companies with more cost-neutral options to replace artificial, petroleum-based dyes. The FDA Commissioner, Marty McCary, stated that the agency took action “within weeks of coming into office to remove all nine petroleum based diets from the US food supply.” He reported that approximately 40% of the food industry pledged to eliminate these dyes within months of the initiative’s launch, with ongoing adoption by other companies.

II. Industry Collaboration & Voluntary Program

While the initial shift is voluntary, the FDA has actively engaged with food companies like Nestle and Kraft Heinz, encouraging them to adopt the changes. The FDA banned one artificial dye with the strongest health concerns, adopting a “win more bees with honey than fire” approach – prioritizing persuasion over immediate regulation.

McCary highlighted a historical precedent, noting that food companies previously responded to societal needs by addressing food insecurity in the 1950s and 60s. He pointed out a disparity in food formulations, with different versions of the same cereal being sold in Canada and the US, with the US version containing petroleum-based dyes. He directly appealed to American companies to offer the healthier version of their products to American children.

III. Potential for Regulation & Health Concerns

The FDA is prepared to transition from a voluntary program to regulation if necessary. McCary emphasized the agency’s willingness to utilize “all the tools in the toolbox,” including considering new evidence regarding the health impacts of individual artificial dyes.

He specifically cited concerns about inflammatory responses triggered by these chemicals, which are not naturally found in the body. These responses have been linked to behavioral disorders, including attention deficit disorder, as evidenced by a large randomized control trial published in BMJ. McCary stated, “we’re going to listen to the medical community and as they present more and more evidence, we will take the liberty and remove any diets using our ban authority if we see fit.”

IV. Expedited Drug Approval Voucher Program

The FDA has implemented an expedited voucher program to accelerate drug approvals, potentially reducing timelines from 10-12 months to 1-2 months. Fifteen vouchers have been awarded to date. This program has faced internal and external criticism regarding safety and potential political influence.

McCary defended the program by stating the FDA is focused on reducing “idle time” in the approval process, not cutting corners on safety. He drew a parallel to clinical practice, emphasizing the urgency of providing treatments to patients as quickly as safely possible. He also acknowledged the partisan climate, suggesting that any FDA action would likely be subject to criticism.

He cited a specific improvement: reducing the time to confirm drug application completeness from 60 days to five minutes using new technology and AI, while still incorporating human review. The agency is challenging “deeply held assumptions” about archaic processes developed in the 1950s and 60s.

V. FDA Staffing & Resource Allocation

The FDA experienced significant staffing changes, particularly in IT, HR, and procurement, with IT personnel reduced from 1,500 to 700 and HR/procurement staff from 2,000 to a couple hundred. However, McCary clarified that no scientific reviewers were laid off.

He asserted that the FDA remains strong and is actively hiring 1,500 scientists, with 110 already in positions and another 400 being onboarded. These cuts were deemed necessary to improve agility and efficiency.

VI. Reshoring Pharmaceutical Manufacturing to the US

The administration is prioritizing the reshoring of pharmaceutical manufacturing to the United States. The FDA is incentivizing this shift by prioritizing applications for facilities built in the US and expediting inspections.

McCary acknowledged the labor challenges, particularly the need for highly skilled workers. He noted that increasing automation is reducing the labor cost differential between US and overseas manufacturing. He framed this effort as undoing the “disaster created by 35 years of globalists moving manufacturing overseas for personal profit.”

The FDA is implementing a “pre-check” program allowing companies to build US manufacturing sites and begin production without waiting for lengthy FDA inspections. He highlighted the recent approval of an antibiotic that will be exclusively produced in the United States, drawing a lesson from the supply chain vulnerabilities exposed during the first year of the pandemic.

Notable Quote:

“We can win more bees with honey than fire.” – Marty McCary, FDA Commissioner, describing the agency’s approach to encouraging industry compliance.

Conclusion:

The FDA is undertaking significant changes across multiple fronts – food dye regulations, drug approval processes, and pharmaceutical manufacturing. These initiatives are driven by a commitment to consumer safety, accelerated access to treatments, and a renewed focus on domestic manufacturing. While some programs face scrutiny, the agency is actively addressing concerns and leveraging technology and strategic incentives to achieve its goals. The overarching theme is a shift towards greater transparency, efficiency, and a prioritization of American interests.